Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy. (19th May 2017)

• Record Type: Journal Article
• Authors: Li, Wenni; Wang, Junlin; Ge, Lina; Shan, Jiehui; Zhang, Chunbing; Liu, Jianping
• Is Part Of: Clinical and experimental hypertension. Volume 39:Number 4(2017)
• Page Start: 382
• Page End: 387
• Publication Date: 2017-05-19
• Subjects: Biomarker -- cystatin C -- diabetic nephropathy (DN) -- early detection -- growth arrest-specific gene 6 (Gas6); Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.1080/10641963.2017.1288739
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: Background : To investigate the diagnostic level of cystatin C and growth arrest-specific gene 6 (Gas6) levels in elderly type 2 diabetic patients with different degrees of diabetic nephropathy (DN). Methods : Four hundred and eighty-two old people, including 130 healthy controls, 130 normoalbuminuric diabetic patients, 122 with microalbuminuria, and 100 with macroalbuminuria, were recruited. Plasma Gas6 and serum cystatin C levels were measured. Results : Plasma Gas6 concentration was significantly lower in diabetic patients with microalbuminuria or macroalbuminuria, as compared with diabetic subjects with normoalbuminuria; while cystatin C was significantly higher. Gas6 was inversely correlated with BMI, WHR, and HbA1c, while cystatin C was inversely correlated with urea nitrogen and creatinine. Multivariate logistic regression analysis showed that, after adjusted for established diabetes risk factors, higher plasma Gas6 was significantly associated with a decreased risk of DN, while higher serum cystatin C was significantly associated with an increased risk. Receiver operating characteristic curve analysis showed that Gas6 was better than cystatin C as a biomarker for early diagnosis and detection of DN, with a cutoff value of 9.435 ng/mL (86.1% sensitivity and 84.6% specificity). Conclusion : Compared to cystatin C, Gas6 may be potentially a better noninvasive diagnostic biomarker for early detection of DN.